Epstein-Barr Virus Infections in Males with the X-Linked Lymphoproliterative Syndrome

  1. HELEN GRIERSON, Ph.D.; and
  2. DAVID T. PURTILO, M.D.
  1. Omaha, Nebraska

    Abstract

    A registry of persons with the X-linked lymphoproliferative syndrome, which is characterized by marked susceptibility to diseases induced by the Epstein-Barr virus, has enrolled 161 patients within 44 kindreds. Fifty-seven percent of the males died of infectious mononucleosis, 29% developed acquired hypogammaglobulinemia, and 24% had malignant lymphoma. The mortality rate was 80%; 70% died by 10 years of age and 100% by 40 years. Thirty-two boys survive, most with malignant lymphoma, acquired hypogammaglobulinemia, or both. We hypothesized that the defective lymphoproliferative control locus on the X chromosome results in unregulated cytotoxic lymphocytic responses to the Epstein-Barr virus; hence, severe hepatitis and virus-associated hemophagocytic syndrome occur with the infectious mononucleosis phenotype. T-cell suppression of immunoglobulin secretion by B cells is responsible for acquired hypogammaglobulinemia. A sustained polyclonal B-cell proliferation probably converts to a monoclonal B-cell malignancy as a result of molecular alterations.

    Article and Author Information

    • ▸From the Departments of Pathology and Microbiology, and Pediatrics, and the Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center; Omaha, Nebraska.

    • Grant support: in part by Public Health Service grant CA30196 from the National Cancer Institute, Department of Health and Human Services, and by a grant from the Lymphoproliferative Research Fund.

    • ▸Requests for reprints should be addressed to David T. Purtilo, M.D.; Department of Pathology and Microbiology, University of Nebraska Medical Center, 42nd St. & Dewey Ave.; Omaha, NE 68105-1065.

    | Table of Contents
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement